AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04268875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same.
Study NCT04646161 — intervention group
Intervention type: DRUG
Intervention: Misoprostol
Description: misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
Study NCT03727087 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment.
Study NCT02194920 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue
Study NCT04086797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AE-103
Description: 1980 mg
Study NCT04086797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01411358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-elderly aged between 18 and 60
Description: one dose of 0.5mL AdimFlu-S
Study NCT01411358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: elderly aged over 60
Description: one dose of 0.5mL AdimFlu-S
Study NCT03963089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume_6mL/kg
Description: Set tidal volume to 6mL/kg for 1 minute
Study NCT03963089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume_10mL/kg
Description: Set tidal volume to 10mL/kg for 1 minute
Study NCT03963089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume_14mL/kg
Description: Set tidal volume to 10mL/kg for 1 minute
Study NCT03963089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid loading
Description: Administer 10mL/kg of crystalloid for 5 minutes
Study NCT01209663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Intermediate Care
Description: Comparison of postoperative Intermediate Care versus Ward Care.
Study NCT01209663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Intermediate Care
Description: Comparison of postoperative Intermediate Care versus Ward Care.
Study NCT00495924 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreatic resection (PD)
Description: PD is a standard therapeutic surgical procedure. No additional interventions are performed.
Study NCT01599871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: theophylline
Description: theophylline 100 mg, twice at day
Study NCT01599871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT03945487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cell
Description: Taken a dose of 1.0\*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.
Study NCT03945487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive treatment
Description: 1. All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~2. Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers).
Study NCT00179400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg
Study NCT00179400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02355119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
Study NCT02355119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT04123288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-709478
Description: 1 film-coated minitablet contains 2 mg of ACT-709478
Study NCT04123288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT-709478
Description: 1 hard capsule contains 10 mg of ACT-709478.
Study NCT01487954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy (EBRT)
Description: Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
Study NCT01487954 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy (EBRT)
Description: Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
Study NCT03110653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
Study NCT02713555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
Study NCT02713555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Sleeve
Description: Gastric Sleeve entails a vertical division of the stomach with a stapler.
Study NCT04102592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permethrin-treated Lesu (baby wrap)
Description: 0.5% permethrin application
Study NCT04102592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Untreated Lesu (baby wrap)
Description: Matching untreated lesu
Study NCT04110093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and PD-1 inhibitor
Description: All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
Study NCT05146531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McCoy laryngoscope
Description: Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.
Study NCT05146531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC D-blade video laryngoscope
Description: Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
Study NCT03110653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
Study NCT01022515 — intervention group
Intervention type: OTHER
Intervention: plasma EM66 & CgA levels assessment
Description: After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
Study NCT01022515 — intervention group
Intervention type: OTHER
Intervention: usual follow up with regular EM66 & Cga levels assessment
Description: Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels.
Study NCT00611468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: All subjects receive treatment with intravenous topotecan and oral erlotinib.
Study NCT00611468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: All subjects receive treatment with intravenous topotecan and oral erlotinib.
Study NCT02439424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reactive ATP
Description: Reactive ATP turned to on
Study NCT02293265 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Short Acting Beta Agonist (SABA)
Description: Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
Study NCT00803348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2
Description: Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
Study NCT00803348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2
Description: Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
Study NCT00803348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
Study NCT04149223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based standardized Cirrhosis order set
Description: Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
Study NCT04149223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-based standardized Cirrhosis order set
Description: Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
Study NCT04233658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x2 capsules / day
Study NCT04233658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cynara Scolymus
Description: 3x2 capsules / day
Study NCT04699812 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROCARDIOGRAM (ECG) PATCH WEAR
Description: ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
Study NCT04207918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
Study NCT04207918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg, by intravenous infusion once a week in 4-6 weeks.
Study NCT04207918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
Study NCT02154048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02154048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Study NCT02154048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02154048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02154048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02948907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Procedure/Bronchoscopy
Description: Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA.
Study NCT03171974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone will be injected intracapsular under US
Study NCT03171974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US
Description: dexamethasone will be injected intracapsular under US
Study NCT02308566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimized Extracorporeal Circulation (MECC)
Description: This group of patients receives surgical aortic valve replacement using MECC.
Study NCT02308566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Extracorporeal Circulation (CECC)
Description: This group of patients receives surgical aortic valve replacement using CECC.
Study NCT02334813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Continuous daily therapy
Study NCT02334813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4-day pulses every 3 weeks
Study NCT02306928 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Study NCT04052984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section
Description: Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
Study NCT00868075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: Twice daily for 8 weeks
Study NCT00868075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy + Exercise Program
Description: Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
Study NCT01671176 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wide diameter bone anchored implant
Description: 4.5 mm wide diameter bone anchored implant
Study NCT01207921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02579525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamical treatment TTP
Description: Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
Study NCT02579525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamical treatment MCG
Description: Based on MAP, CVP, urine output monitoring
Study NCT02672306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
Study NCT02672306 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
Study NCT04479306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT04479306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT04148378 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study NCT04160559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: green tea
Description: The investigators require patients to regularly drink green tea during the trial period.
Study NCT04160559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green tea
Description: The investigators require patients to regularly drink green tea during the trial period.
Study NCT01858272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H5.020CMV.PDGF-b and limb compression bandage
Study NCT02953977 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Prevention Program
Description: An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
Study NCT02953977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
Study NCT00710866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)
Description: Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
Study NCT00710866 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)
Description: Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
Study NCT00631566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%
Description: BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days.
Study NCT00631566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
Study NCT01481142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (GMA) Adsorptive Apheresis
Description: Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
Study NCT04021173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide
Description: 5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
Study NCT04021173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
Study NCT00016367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15.
Study NCT00016367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1.
Study NCT00016367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.
Study NCT00912080 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genomic signature
Description: genomic signature analysis
Study NCT02253823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV
Study NCT02253823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV/RTV - low dose
Study NCT02253823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV/RTV - high dose
Study NCT01410656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Implementation Intention
Description: Telephone implementation intention counseling
Study NCT01410656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-completed implementation intention
Description: Self-administered implementation intention intervention